Gastrointestinal dysmotility in a patient with advanced lung cancer: paraneoplastic or drug-induced?

BMJ Case Rep

Clínica Médica, Universidade Federal de Minas Gerais Faculdade de Medicina, Belo Horizonte, Minas Gerais, Brazil.

Published: January 2021

A 75-year-old man was hospitalised for bronchoscopy with biopsy due to a suspicious pulmonary mass at chest tomography. He had significant dyspnoea, constipation, nausea, vomiting, anorexia and a 33% loss of weight in the past 3 months. Biopsy revealed a pulmonary squamous cell carcinoma, which was inoperable. Tramadol used at home for 3 months was replaced by morphine on admission. The patient remained constipated despite prokinetics and laxatives, leading to the diagnostic hypothesis of paraneoplastic motility disorder and opioid-induced constipation. Abdominal tomography ruled out the possibility of mechanical obstruction. As complications, the patient presented superior vena cava syndrome and opioid (morphine) intoxication. The patient died a few days later. The management of this case highlights the importance of multidisciplinary care and the challenges of palliative oncology care. Paraneoplastic motility disorder must always be considered among the mechanisms of intestinal dysfunction in patients with advanced oncological disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839852PMC
http://dx.doi.org/10.1136/bcr-2020-237835DOI Listing

Publication Analysis

Top Keywords

paraneoplastic motility
8
motility disorder
8
gastrointestinal dysmotility
4
patient
4
dysmotility patient
4
patient advanced
4
advanced lung
4
lung cancer
4
cancer paraneoplastic
4
paraneoplastic drug-induced?
4

Similar Publications

We aimed to define the clinical features and outcomes of encephalitis associated with anti-GAD65 Abs. In addition, we reviewed cases published in the literature with GAD65 encephalitis. We retrospectively studied 482 consecutive patients attending a tertiary care center for evaluation of an autoimmune neurological disorder.

View Article and Find Full Text PDF

Background: Autoimmune encephalitis (AE) is a disease caused by an abnormal reaction between the body's autoimmunity and the central nervous system, in which the abnormal immune response targets antigenic components within or on the surface of neuronal cells. The main manifestations are mental and behavioural changes, cognitive impairment, impaired consciousness, seizures, movement disorders, etc. Most cell surface antibodies respond well to immunotherapy, intracellular antibodies, on the other hand, are usually associated with more tumours and are relatively difficult to treat with a poor prognosis.

View Article and Find Full Text PDF
Article Synopsis
  • Ocular flutter is a rare neurological disorder marked by fast, irregular eye movements, often linked to autoimmune diseases or infections, yet the specific brain regions involved are still unclear.
  • A case study of a 15-year-old male with ocular flutter revealed high levels of anti-sulfatide antibodies, prompting treatment with intravenous immunoglobulin (IVIG), which successfully resolved his symptoms.
  • This case highlights the need for sulfatide antibody testing in unusual cases of ocular flutter and suggests that IVIG might be an effective treatment for conditions associated with these antibodies.
View Article and Find Full Text PDF

Neuro-Oncological Ventral Antigen 1 () is best known for its role in mediating an alternative splicing (AS) program in neurons, yet was first discovered as an antigen expressed in breast tumors, causing rare autoimmune reactions and paraneoplastic neurological disorders (PNDs). The PND model suggests a plausible role of the tumor antigen expression in tumor suppression, whereas it has emerged that NOVA may function as an oncogene in a variety of cancers. In addition, whether NOVA mediates AS in breast cancer remains unanswered.

View Article and Find Full Text PDF

N4-acetylcytidine (ac4C) is essential for the development and migration of tumor cells. According to earlier research, N-acetyltransferase 10 (NAT10) can increase messenger RNAs (mRNAs) stability by catalyzing the synthesis of ac4C. However, little is known about NAT10 expression and its role in the acetylation modifications in prostate cancer (PCa).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!